Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an announcement.
Chimeric Therapeutics Ltd. announced the issuance of 25 million fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) as of March 17, 2025. This move is part of previously announced transactions and is expected to enhance the company’s capital base, potentially supporting its ongoing research and development efforts in the field of cancer therapeutics.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of innovative cell therapies for cancer treatment. The company is dedicated to advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies to address unmet medical needs in oncology.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$7.98M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.